Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.
Status:
Recruiting
Trial end date:
2025-10-16
Target enrollment:
Participant gender:
Summary
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose
expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary
anti-tumor activity of ABM-168 in adult patients with RAS or RAF or NF-1 mutated advanced
solid tumors as ABM-168 may have a significant effect in inhibiting cell growth.